An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis

Graham Devereux, Sandra Steele, Timothy Jagelman, Shona Fielding, Robert Muirhead, Jeff Brady, Christal Grierson, Richard Booker, John Winter, Tom Fardon, Jonathan McCormick, Jeffrey Huang, Douglas Miller

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)
26 Downloads (Pure)


Background: In cystic fibrosis (CF), cross-sectional studies have reported sputum matrix metalloproteinase (MMP)-9 to be elevated and negatively
correlated with FEV1. This longitudinal study examined the association between MMP-9 and tissue inhibitors of metalloproteinases (TIMPs) to
prognostic parameters in CF.
Method: A cross-sectional survey of CF and control subjects; CF patients were followed up for a median of 49 months. MMP-9 and TIMP-1 and
TIMP-2 were quantified in sputum and plasma.
Results: Seventy-three patients with CF, median age 22 years, and 40 controls were recruited. Fifty-three of these CF patients were followed up.
Prospectively, in CF subjects, plasma MMP-9 activity was adversely associated with FEV1 (β −1.15 (95% CI −2.10, −0.20), p = 0.019) and rate
of FEV1 decline, and plasma TIMP-1 was adversely associated with mortality: hazard ratio 3.66 (1.91–7.04), p b 0.001.
Conclusions: These associations further justify investigation of MMP-9 and TIMP-1 as biomarkers for short- to medium-term FEV1 decline and
mortality in patients with CF.
Original languageEnglish
Pages (from-to)557-563
Number of pages7
JournalJournal of Cystic Fibrosis
Issue number5
Early online date10 Feb 2014
Publication statusPublished - Sept 2014

Bibliographical note

This work was supported by awards from the University of Aberdeen Development Trust and (TMRC INF_AU_124) from the Translational Medicine Research Collaboration — a consortium made up of the Universities of Aberdeen, Dundee, Edinburgh and Glasgow, the four associated NHS Health Boards (Grampian, Tayside, Lothian and Greater Glasgow & Clyde), Scottish Enterprise and Wyeth Pharmaceuticals. We would like to acknowledge the help of Mrs Irene Pucci who collected the paediatric samples in Aberdeen, Mrs Gillian Moir who processed the sputum and blood samples in Aberdeen, and Nicola Stevens and Dr Anna Tommasi who were involved in the collection and processing of samples in Dundee.


  • cystic fibrosis
  • FEV1
  • MMP-9
  • TIMP-1
  • mortality


Dive into the research topics of 'An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis'. Together they form a unique fingerprint.

Cite this